Cancer News and Research

Latest Cancer News and Research

BioLineRx completes pre-clinical development of BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.

17 Oct 2012

Transvaginal ultrasound effective in treating early-stage endometrial cancer

A common birth control device is effective in treating early-stage endometrial cancer in morbidly obese and high-risk surgery patients, said Georgia Health Sciences University Cancer Center researchers, and could lead to a cost-effective treatment for all women with this cancer type.

17 Oct 2012

Brachyury variation may increase risk of chordoma

A genetic variation possessed by 40% of the population is associated with a five-fold increase in risk for developing chordoma, a cancer that strikes the bones of the skull and spine.

17 Oct 2012

Resverlogix commences RVX-208 Phase 2 trial in pre-diabetes mellitus

Resverlogix Corp. today announced that it has initiated an exploratory Phase 2 clinical trial in patients with pre-diabetes mellitus to examine the effects of RVX-208 and ApoA-I production on glucose metabolism.

17 Oct 2012

State roundup: Many states, cities cut retiree health benefit budgets; Feds to decide Georgia's benchmark benefits plan

As cash-strapped U.S. cities and states struggle to address gaping budget holes, a long-honored benefit for public-sector workers has come into the cross-hairs of budget cutters: retiree health insurance. A growing number of states and cities are eliminating or reducing health coverage for retirees, a benefit that has long fallen by the wayside for most private-sector workers.

16 Oct 2012

Kids encouraged to Stand Up for their health and be active

Children and adolescents are accumulating up to eight hours of sitting on a daily basis, research to be presented at Australia’s paramount sports medicine, sports science, sports injury prevention and physical activity promotion conference, be active2012 will show (October 31- November 3, Sydney).

16 Oct 2012

Nine Sydney researchers to receive funding for biomedical research projects

The Ramaciotti Foundations will award nearly $645,000 in grants to nine Sydney researchers at a gala dinner tonight, to support continued outstanding biomedical research. The Ramaciotti Foundations will award over $1.6 million to 23 recipients at the annual awards evening in Brisbane.

16 Oct 2012

FDA approves Hologic’s APTIMA HPV 16 18/45 Genotype Assay for use on TIGRIS system

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's APTIMA HPV 16 18/45 Genotype Assay for use on its TIGRIS instrument system.

From Hologic, Inc. 16 Oct 2012

First analysis of IASLC malignant pleural mesothelioma database

The International Mesothelioma Interest Group (IMIG) staging system has been widely used, however, widespread concerns exist about the validity of the current malignant pleural mesothelioma (MPM) staging system.

16 Oct 2012

Study identifies multipotent and unipotent stem cells that contribute to prostate postnatal development

Publication in Nature Cell Biology advanced on line publication: researchers at the Université Libre de Bruxelles, ULB identify multipotent and unipotent Stem Cells (SCs) that contribute to prostate postnatal development.

16 Oct 2012

First Edition: October 16, 2012

Today's early morning highlights from the major news organizations, including reports about a study regarding the possible impact of premium support on Medicare premiums.

16 Oct 2012

LRRK2 inhibitors may provide neuroprotection for patients with Parkinson's

For decades, patients with Parkinson's disease (PD) have had the same experience. Their hands start to shake uncontrollably, their limbs become rigid and they lose their balance. Years before those movement problems set in, many begin struggling with fainting, incontinence, sexual dysfunction, anxiety and depression. Many patients are still treated with a 42-year-old drug called L-DOPA, which temporarily staves off symptoms but can itself cause heart arrhythmias, stomach bleeding and hallucinations.

16 Oct 2012

Gravity changes affect immune system development

New research findings recently published in The FASEB Journal, show that immune system development is affected by gravity changes, as reported by researchers from the University of Lorraine and University of Luxembourg. Astronauts are exposed to stresses, during launch and landing, which disrupts their body's natural defenses against infection. Changes to the immune system need to be investigated before astronauts undergo longer space missions.

16 Oct 2012

Computerized checklist helps physicians to prevent dangerous venous thromboembolisms or PE

A computerized checklist system designed to help physicians identify and use the best methods of preventing potentially deadly blood clots in hospitalized trauma patients dramatically reduced the number of these dangerous venous thromboembolisms (VTEs), new Johns Hopkins research suggests.

16 Oct 2012

Viewpoints: Cancer doctors reject 'phenomenally expensive' new drug; Protecting patients' rights

At Memorial Sloan-Kettering Cancer Center, we recently made a decision that should have been a no-brainer: we are not going to give a phenomenally expensive new cancer drug to our patients.

16 Oct 2012

Thymic stromal lymphopoietin molecule makes mice resistant to skin cancer

A molecule involved in asthma and allergies has now been shown to make mice resistant to skin cancer, according to scientists at Washington University School of Medicine in St. Louis.

16 Oct 2012

Radioactive gold nanoparticle treatment safe and effective in dogs with prostate cancer

Currently, large doses of chemotherapy are required when treating certain forms of cancer, resulting in toxic side effects. The chemicals enter the body and work to destroy or shrink the tumor, but also harm vital organs and drastically affect bodily functions. Now, scientists at the University of Missouri have proven that a new form of prostate cancer treatment that uses radioactive gold nanoparticles, and was developed at MU, is safe to use in dogs.

16 Oct 2012

Researcher uncovers mechanisms involved in prognosis of acute myeloid leukemia

When patients suffering from Acute Myeloid Leukemia (AML) express high levels of the gene, MN1, an already aggressive leukemia is accelerated and shortens survival time. While that's a known fact, the mechanisms involved aren't well understood which is why a Wake Forest Baptist Medical Center researcher decided to take a closer look.

16 Oct 2012

VeriStrat identifies NSCLC patients likely to respond to erlotinib

A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit from erlotinib. The study was conducted on a subset of patients enrolled in the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced non-small cell lung cancer patients.

16 Oct 2012

Fit elderly NSCLC patients should be considered for salvage targeted therapy

Until there are more validated biomarkers to direct treatment decisions, many physicians use patient age to decide what therapy to give their patients. Literature data report that older patients often go undertreated because of concerns for limited tolerance to toxic therapies.

16 Oct 2012